Janux Therapeutics, Inc. (JANX) fair value analysis
Nasdaq · Updated 2026-10-19
JANX price how computed
Valuation status
No fair-value estimate yetJANX has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for JANX yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $16.51
- Sector
- Healthcare
- 12-month range
- $12.18–$34.74
- Market cap
- $1.01B
- From 52-week high
- -52.5%
- Shares outstanding
- 61.1M
- Rank in Healthcare by quality score
- #104 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Janux Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and other diseases. The company operates in the United States as a member of the Healthcare sector listed on the Nasdaq exchange.
JANX currently ranks #104 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $1.01B
- P/E (trailing)
- n/m
- Revenue (TTM)
- $31.9M
- Net margin
- -321.8%
- EPS (TTM)
- $-1.64
- Gross margin
- 100.0%
- Debt / equity
- 0.02
- Revenue growth (3-yr avg)
- 102.6%
- Shares outstanding
- 61.1M
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Expanding
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 44 · neutral
- 50-day average
- $17.47
- 200-day average
- $15.16
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-05
- Last 8 quarters vs consensus
- 5 beat, 3 missed
- Quarter by quarter
- 2026-06 ▼ miss (-34.6%)
2026-03 ▲ beat (+25.0%)
2025-12 ▲ beat (+21.5%)
2025-09 ▲ beat (+36.1%)
2025-06 ▼ miss (-14.6%)
2025-03 ▲ beat (+2.6%)
2024-12 ▲ beat (+15.6%)
2024-09 ▼ miss (-41.7%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 16 buy · 1 hold · 1 sell (18 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $36.2
- Target vs last price
- +119.3%
What our data shows for JANX
- Shares are trading in the lower third of their 12-month price range of $12.18–$34.74.
- The 14-day relative strength index sits at a neutral 44.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- JANX's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the JANX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — # JANX Weekly Indicator Summary TickrTrends' derived indicators for JANX, a healthcare sector stock, showed a shift in trend momentum this week. The 50/200-day trend state moved from an uptrend to a mixed state, suggesting reduced directional conviction. The current valuation verdict remains awaiting full valuation.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — JANX, a healthcare sector stock, showed a shift in its 50/200-day trend state this week, moving from a mixed trend to an uptrend. The company's derived indicators reflect this technical development. The valuation verdict for JANX remains awaiting full valuation.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is JANX stock undervalued?
TickrTrends has no fair-value estimate for JANX yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is JANX's TickrTrends verdict?
JANX is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does JANX compare to other Healthcare stocks?
JANX ranks #104 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is JANX overbought or oversold?
JANX's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does JANX report earnings next?
JANX's next earnings report is scheduled for 2026-11-05, per the published earnings calendar.
Does JANX usually beat earnings estimates?
Over its last 8 reported quarters JANX beat the consensus estimate 5 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about JANX?
Of 18 analysts covering JANX, 16 rate it a buy, 1 a hold and 1 a sell - buy-leaning, with a consensus price target of $36.2 (+119.3% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.